Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.46 |
| ▸ | CSF1R | P07333 | 20/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23482820 | 0.94 | EGFR (0.52) | EGFRCSF1RPDGFRBKITFGFR1 | |
| SCHEMBL26272241 | 0.75 | EGFR (0.83) | EGFRCSF1RPDGFRBKITFGFR1 | |
| SCHEMBL23476142 | 0.74 | EGFR (0.47) | EGFRCSF1RPDGFRBKITFGFR1 | |
| SCHEMBL29458711 | 0.69 | TNK2 (0.56) | EGFRCSF1RPDGFRBKITFGFR1 | |
| SCHEMBL23476141 | 0.67 | EGFR (0.79) | EGFRCSF1RPDGFRBKITFGFR1 | |
| SCHEMBL3979713 | 0.66 | FGFR4 (0.52) | EGFRCSF1RFGFR1FGFR2FGFR4 | |
| SCHEMBL3974703 | 0.66 | FGFR4 (0.51) | EGFRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL3969621 | 0.65 | FGFR4 (0.51) | EGFRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL24490202 | 0.65 | FGFR4 (0.56) | FGFR1FGFR2FGFR4FGFR3FLT3 | |
| SCHEMBL5768493 | 0.64 | FGFR4 (0.57) | EGFRPDGFRBFGFR1PDGFRAFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233696-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233696-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | FUT6, FUT5, OGT | EGFR 2391/4885CSF1R 2354/4885PDGFRB 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.